Financial Statements

Innate Pharma S.A. (IPH.PA)

2.67 €

+0.02 (+0.75%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2020 2019 2018 2017 2016
Retained Earnings (Previous Year) -156-135-152-104-
Net Income -64-213-4813
Stock Dividends -1-014--116
Dividend Paid -----
Retained Earnings -220-156-135-152-104

PPE Schedule

Year 2020 2019 2018 2017 2016
Gross PPE 1210119-
Annual Depreciation 11671818
Capital Expenditure -11-65-1-6-9
Net PPE 121210119

Intangible and Goodwill Schedule

Year 2020 2019 2018 2017 2016
Intangible and Goodwill (Previous Year) -----
New Purchases -18-43---3
Intangible and Goodwill -----

Innate Pharma S.A. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Innate Pharma S.A. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.